Nasal septum perforation in a breast cancer patient treated with bevacizumab.
Marín
A Pinto
AP
Sánchez
A Redondo
AR
Arranz
E Espinosa
EE
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008408:Mastectomy; D009300:Nasal Septum / Q000473:pathology*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009367:Neoplasm Staging; D009668:Nose Diseases / Q000139:chemically induced*; D011878:Radiotherapy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab